Publicaciones en colaboración con investigadores/as de Hospital Universitario Puerta de Hierro (45)

2023

  1. Alcohol-related liver disease phenotype impacts survival after an acute variceal bleeding episode

    Liver International, Vol. 43, Núm. 7, pp. 1548-1557

  2. Hepatic encephalopathy is not a contraindication to pre-emptive TIPS in high-risk patients with cirrhosis with variceal bleeding

    Gut, Vol. 72, Núm. 4, pp. 749-758

  3. Metabolomics as a tool to predict the risk of decompensation or liver-related death in patients with compensated cirrhosis

    Hepatology (Baltimore, Md.), Vol. 77, Núm. 6, pp. 2052-2062

  4. Tenofovir Disoproxil Fumarate Reduces the Severity of COVID-19 in Patients with Chronic Hepatitis B

    Digestive Diseases and Sciences, Vol. 68, Núm. 6, pp. 2731-2737

2022

  1. Decreased Long-Term Severe Acute Respiratory Syndrome Coronavirus 2–Specific Humoral Immunity in Liver Transplantation Recipients 12 Months After Coronavirus Disease 2019

    Liver Transplantation, Vol. 28, Núm. 6, pp. 1039-1050

  2. Non-invasive tests for clinically significant portal hypertension after HCV cure

    Journal of Hepatology, Vol. 77, Núm. 6, pp. 1573-1585

2021

  1. Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosis

    Journal of Hepatology, Vol. 75, Núm. 3, pp. 589-599

  2. Bacterial infections in patients with acute variceal bleeding in the era of antibiotic prophylaxis

    Journal of Hepatology, Vol. 75, Núm. 2, pp. 342-350

  3. Mild AST elevation as an early sign of COVID-19 severity in a multicenter Madrid cohort

    Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva, Vol. 113, Núm. 11, pp. 780-786

  4. Serum miR-181b-5p predicts ascites onset in patients with compensated cirrhosis

    JHEP Reports, Vol. 3, Núm. 6

  5. Tacrolimus as an Effective and Durable Second-Line Treatment for Chronic Autoimmune Hepatitis: A Multicentric Study

    Digestive Diseases and Sciences, Vol. 66, Núm. 8, pp. 2826-2832

2020

  1. Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension

    Journal of Hepatology, Vol. 73, Núm. 6, pp. 1415-1424

  2. Elevation of Liver Fibrosis Index FIB-4 Is Associated With Poor Clinical Outcomes in Patients With COVID-19

    The Journal of infectious diseases, Vol. 222, Núm. 5, pp. 726-733

  3. Persistence of clinically significant portal hypertension after eradication of hepatitis C virus in patients with advanced cirrhosis

    Clinical Infectious Diseases, Vol. 71, Núm. 10, pp. 2726-2729

  4. Plasma metabolomic fingerprint of advanced cirrhosis stages among HIV/HCV-coinfected and HCV-monoinfected patients

    Liver International, Vol. 40, Núm. 9, pp. 2215-2227

  5. Prevalence, features and predictive factors of liver nodules in Fontan surgery patients: The VALDIG Fonliver prospective cohort

    Journal of Hepatology, Vol. 72, Núm. 4, pp. 702-710

2019

  1. Alcohol-related liver disease. Clinical practice guidelines. Consensus document sponsored by AEEH

    Gastroenterologia y Hepatologia, Vol. 42, Núm. 10, pp. 657-676

  2. HIV coinfection predicts failure of ledipasvir/sofosbuvir in treatment-naïve noncirrhotic patients with HCV genotype

    Open Forum Infectious Diseases, Vol. 6, Núm. 5

  3. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial

    The Lancet, Vol. 393, Núm. 10181, pp. 1597-1608

2018

  1. Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline

    Gastroenterologia y Hepatologia, Vol. 41, Núm. 5, pp. 328-349